This article is based on a poster originally authored by Ariane Jonetz-Mentzel et al. In biopharmaceutical laboratories, there is an increasing demand for label-free, high-throughput screening based ...

Fragment-based drug design (FBDD) has led to a revolution in contemporary drug discovery, facilitating a bottom-up approach to the identification and evolution of bioactive small molecules into viable ...

Conventional high throughput screening for clinical candidates cannot evaluate over 99% of commercially available molecules, thereby restricting the accessible chemical search space for therapeutic ...

Messenger RNA (mRNA) technology came of age during COVID-19 with several vaccines and therapeutics coming to market. However, since the height of the pandemic, the flow of new mRNA-based products has ...